Definition and Pathophysiology of Asthma in addition to classification and recent updates in the management of asthma based on GINA-2019 Guidelines, by Dr. Marco Makram.
2. Asthma is a chronic airway inflammation
characterized by:
History of Respiratory symptoms
that vary in intensity over time,
these symptoms include:
Wheezing
Shortness of
breath
Chest
tightness
Cough
Definition of Asthma
Variable expiratory
airflow limitation.
FEV1 & PEF
variability
FEV1: Forced Expiratory Volume in the 1st second
PEF: Peak expiratory flow
4. Peak Expiratory
Flow (PEF)
PEF is the flow
(speed)
of air coming out
of the lung during
forced expiration.
Peak Flow Meter
device
5. Allergic Asthma is the most common form of asthma
which results from an inappropriate immune
response to common inhaled proteins (or allergens)
(environmental exposure) in genetically susceptible
individuals.
Asthma phenotypes
Allergic Asthma
(Extrinsic):
- Associated with a past family history of
Allergic diseases such as:
• Allergic Rhinitis (AR) • Eczema
• Food/drug allergy
6.
7.
8.
9. - Individuals with Allergic asthma
are termed
atopic asthmatics and exhibit
Ig-E reactivity
to specific antigens.
Allergic Asthma
- Examination of the induced sputum in these
patients reveals high level of eosinophils.
- These patients usually respond well to inhaled
corticosteroids (ICS) treatment.
10. The T-cell receptor,
or TCR,
Molecule found on the
surface of T cells,
or T lymphocytes, that
is responsible for
recognizing fragments
of antigen as peptides
bound to major
histocompatibility
complex (MHC)
molecules.
11. The main function
of MHC molecules
(major
histocompatibility
complex)
is to bind
to antigens derived
from pathogens
and display them
on the cell surface
for recognition by
the appropriate
T-cells.
12.
13.
14.
15. Asthma has been considered a T helper 2 (TH2) cell-
associated inflammatory disease,
and
TH2-type cytokines, such as interleukin-4 (IL-4), IL-5 and IL-
13,
Cytokines Attracts &
Activates
Eosinophils
Type 2, T HELPER Cells
Involved in:
Asthma
Atopic Dermatitis
Allergic Rhinitis
Atopic Triad
INTERLEUKIN 5 (IL
5)
16.
17.
18.
19. Asthma phenotypes
Non-allergic Asthma (Intrinsic)
This type of asthma is not associated with allergic reactions.
No relation of intrinsic asthma to inhaled
substances or food.
(not driven by a specific allergen).
No family history of Allergy.
No Urticaria, eczema or other associated allergic manifestations.
20. Neutrophilic Asthma
is more severe than
Th2/ Eosinophilic.
The cellular profile of the
sputum of these patients
may be Neutrophilic or
contains a few
inflammatory cells.
Patients with non-
allergic asthma often
respond
less well
to inhaled corticosteroids
(ICS).
Non-allergic Asthma (Intrinsic)
IL8
Plays key
role
In Asthma
Mechanism of
Promoting
Asthma is
Unknown
Neutrophils:
Highly inflammatory
Phagocytic
21.
22.
23. Medical
Department
Diagnostic features & Asthma criteria
Diagnostic feature Asthma Criteria
1- History of variable
respiratory symptoms:
• Wheezing
• Shortness of breath
• Chest tightness
• Cough
• More than one type of respiratory symptoms (wheeze,
shortness of breath, cough, chest tightness).
• Isolated cough with no other respiratory symptoms
decreases the probability that symptoms are due to
asthma.
• Symptoms occur variably over time and vary in
intensity.
• Symptoms are often worse at night or on waking.
24. Diagnostic features Asthma Criteria
2- Variability in lung functions &
documented expiratory airflow
limitation according to the following
tests:
• Positive BD (Bronchodilator)
reversibility test.
• Excessive variability in twice
daily PEF over 2 weeks.
• Significant increase & improvement
of lung function after 4 weeks of
anti-inflammatory treatment
• The greater the variation, the more confident the diagnosis.
• Increased in FEV1>12% and >200 ml from
baseline after BD indicates asthma (in adults).
• Average daily diurnal PEF variability > 10% (in
adults)
• Increase in FEV1 by > 12% and 200 ml (or PEF by > 20%)
from baseline after 4 weeks of treatment.
Diagnostic features & Asthma criteria
Medical
Department
25. Step 2: Mild Persistent
Step 1: Mild intermittent
Classification of Asthma
Symptoms
:
Less than or equal 2 times a week &
asymptomatic between
exacerbations.
Night-time
symptoms:
Not more than 2 times per month
Lung functions: FEV1 Or PEF higher than or equal 80%
predicted
PEF Variability less than 20%
Symptoms
:
Night-time
symptoms:
Lung functions:
More than 2 times a week
But Less than daily
symptoms
More than 2 times per
month
FEV1 or PEF higher than or equal 80%
predicted.
PEF Variability from 20% to 30%.
26. Classification of Asthma
Step 3: Moderate
Persistent
Step 4: Severe Persistent
Symptoms
:
Symptoms
:
Night-time
symptoms:
Night-time
symptoms:
Lung functions:
Lung functions:
Symptoms are daily
Daily use of Short-acting Beta2-agonists
(SABA)
More than once per week
FEV1 Or PEF higher than 60%
and less than 80% predicted.
PEF Variability higher than 30%
- Continual daily
symptoms
- Frequent ExacerbationsFrequent Nocturnal
symptoms
FEV1 Or PEF Less than 60%
Predicted
PEF Variability higher than 30%
27. Q. What are the differences between controller and
reliever medications that used for management of
Asthma..??
CONTROLLER MEDICATION
• These are used for regular
maintenance treatment
(Long-term).
• They reduce airway inflammation,
control symptoms, and reduce future
risks of exacerbations and decline in
lung function.
• Examples include:
• Low dose ICS
• Low dose ICS/LABA
• Moderate/High dose ICS/LABA
RELIEVER (RESCUE) MEDICATION
• These are provided for as-needed relief
(Short-term) of breakthrough emerging
symptoms during worsening asthma or
exacerbations.
• Examples include:
• As-needed short-acting beta2-agonist (SABA) as
Salbutamol.
• Formoterol to replace SABA.
• Low dose ICS/Formoterol as maintenance and
reliever therapy.
With population-level risk reduction strategies, short-term clinical benefit may not necessarily be seen in individual patients. The aim is to reduce the probability of serious adverse outcomes at a population level.
The dotted line around Step 1 indicates that the evidence is indirect